30 October 2017



Companies Announcement Office ASX Limited Level 6, 20 Bridge Street Sydney NSW 2000

PERFORMANCE INCENTIVES TO KEY EMPLOYEES, CONSULTANT AND DIRECTORS

The Company has proposed a number of incentives to key employees, consultant and executive director and non-executive director.

Key Employees

IIIO BSN IBUOSIBO

In accordance with the Incentive Performance Rights Plan, the Company has issued a total of 350,000 performance rights to key employees. These issues are issued under Listing Rule 7.2 exception 9 and do not form part of the capacity that the Company has under Listing Rule 7.1.

The incentives are important for key staff retention and a reward for performance and are summarised as follows:

50,000 - performance rights issued and immediate vesting and conversion to ordinary shares 150,000 - issued and vest and convert to ordinary shares on 15 January 2019 if remain Eligible Participant

150,000 - issued and vest and convert to ordinary shares on 15 January 2020 if remain Eligible Participant

Eligible participant means remaining a director, employee or consultant of the Company.

Consultant-Brian E Joseph – SENIOR SCIENTIFIC ADVISOR

Subject to shareholder approval, the Company proposed to grant the following performance rights to Brian E Joseph (or his nominee):

166,666 – issued and vest and convert to ordinary shares on 15 January 2019 if remain Eligible Participant (which condition is subject to still being retained in this role by the Company)

166,666 - issued and vest and convert to ordinary shares on 15 January 2020 if remain Eligible Participant

166,667 - issued and vest and convert to ordinary shares on 15 January 2021 if remain Eligible Participant

Executive Director - Alain F. Bouruet-Aubertot (or his nominee)

Further to the announcement of 10 July 2017, Alain F. Bouruet-Aubertot has been appointed as Executive Director and the Board has agreed to amend his remuneration with the performance remuneration being subject to shareholder approval. The terms of the remuneration package is summarised as follows:

Salary: US\$150,000 per annum, subject to completion of financing, and effective 1 November 2017

30 October 2017



Performance remuneration, subject to shareholder approval, and ASX Listing Rules:

A total of 3,350,000 performance rights to vest as follows, subject to remaining an Eligible Participant:

100,000 Performance Rights vest and become exercisable upon full commissioning of Phase 1 with start up on or before 15 August 2018 (Performance Rights are reduced by 20% per month of delay (pro-rata));

120,000 Performance Rights will vest and become exercisable upon the Company achieving three concurrent monthly sales of 1,666cft pm – equating to 80% of monthly annual nameplate capacity potential of 2,083cft pm – on or before 31 December 2018 (Performance Rights are reduced by 33% per month of delay (pro-rata));

150,000 will vest and become exercisable upon full commissioning of Phase 2 with start up on or before 1 April 2019 ([Performance Rights are reduced by 20% per month of delay (prorata)):

180,000 Performance Rights will vest and become exercisable upon the Company achieving three concurrent monthly sales of 4,800cft pm – equating to 80% of monthly annual nameplate capacity potential of 6,000cft pm – on or before 30 September 2019 ((Performance Rights are reduced by 33% per month of delay (pro-rata));

300,000 Performance Rights will vest and become exercisable upon the installation of additional autoclave and/or kiln capacity (as extension of Phase 2 – ON SITE) which lifts confirmed nameplate capacity to at least 100,000cft pa on or before 31 December 2019,

750,000 performance rights - 30 day volume weighted average share price (VWAP) for the shares on ASX is \$0.60 or higher from the date of issue

750,000 performance rights - 30 day VWAP for the shares on ASX is \$0.90 or higher from the date of issue

500,000 performance rights - 30 day VWAP for the shares on ASX is \$1.05 or higher from the date of issue

500,000 performance rights - 30 day VWAP for the shares on ASX is \$1.20 or higher from the date of issue

Non-executive Director - Todd Hoare

Performance remuneration, subject to shareholder approval, and ASX Listing Rules:

A total of 150,000 performance rights to vest as follows, subject to remaining an Eligible Participant:

30 October 2017



75,000 performance rights - 30 day volume weighted average share price (VWAP) for the shares on ASX is \$0.60 or higher from the date of issue

75,000 performance rights - 30 day VWAP for the shares on ASX is \$0.90 or higher from the date of issue

For further details, please contact:

Simon Hinsley

NWR Communications

E: simon@nwrcommunications.com.au

P: +61-401-809-653

Alain F. Bouruet-Aubertot

Executive Director

AIUO BSD IBUOSIBO

E: abouruet@CFOAM.com

Toby Chandler

Non-Executive Director

E: tchandler@CFOAM.com

Todd Hoare

Non-Executive Director

E: thoare@CFOAM.com

Gary Steinepreis

Non-Executive Chairman

E: gsteinepreis@CFOAM.com

About CFOAM Limited

CFOAM® is an inorganic carbon material that is manufactured from coal, pitch or lignin feedstock. CFOAM® manufactured in this process has a rigid foam structure, similar in appearance to pumice stone, but with entirely different properties. CFOAM® is currently used across a wide variety of markets including composite tooling for the aerospace sector, energy absorbing applications and defence applications. Additional markets such as the automotive applications for energy absorption and fire resistance are also expected become significant to the Company over time.

CFOAM® was developed to meet the growing demand for ultra-high-end performance engineering materials in the, industrial, aerospace, military and commercial product markets.

Important Notice

Some of the statements appearing in this announcement may be in the nature of forward looking statements. You should be aware that such statements are only predictions and are subject to inherent risks and uncertainties. Those risks and uncertainties include factors and risks specific to the industries in which CFO operates and proposes to operate as well as general economic conditions, prevailing exchange rates and interest rates and conditions in the financial markets, among other things. Actual events or results may differ materially from the events or results expressed or implied in any forward looking statement. No forward looking statement is a guarantee or representation as to future performance or any other future matters, which will be influenced by a number of factors and subject to various uncertainties and contingencies, many of which will be outside CFO's control.

CFO does not undertake any obligation to update publicly or release any revisions to these forward looking statements to reflect events or circumstances after today's date or to reflect the occurrence of

30 October 2017



unanticipated events. No representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information, opinions or conclusions contained in this announcement. To the maximum extent permitted by law, none of CFO, its directors, employees, advisors or agents, nor any other person, accepts any liability for any loss arising from the use of the information contained in this announcement. You are cautioned not to place undue reliance on any forward looking statement. The forward looking statements in this announcement reflect views held only as at the date of this announcement.

This announcement is not an offer, invitation or recommendation to subscribe for, or purchase securities by CFO. Nor does this announcement constitute investment or financial product advice (nor tax, accounting or legal advice) and is not intended to be used for the basis of making an investment decision. Investors should obtain their own advice before making any investment decision. By reviewing or retaining this announcement, you acknowledge and represent that you have read, understood and accepted the terms of this important notice.

